Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC

BACKGROUND: No biomarker is available to predict prognosis of patients with advanced ovarian cancer (AOC) and guide the choice of chemotherapy. We performed a prospective-retrospective biomarker study within the MITO2 trial on the treatment of AOC. Patients and methods: MITO2 is a randomised multice...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Oncotarget
المؤلفون الرئيسيون: Perrone, Francesco, Baldassarre, Gustavo, Indraccolo, Stefano, Signoriello, Simona, Chiappetta, Gennaro, Esposito, Franca, Ferrandina, Gabriella, Franco, Renato, Mezzanzanica, Delia, Sonego, Maura, Zulato, Elisabetta, Zannoni, Gian F., Canzonieri, Vincenzo, Scambia, Giovanni, Sorio, Roberto, Savarese, Antonella, Breda, Enrico, Scollo, Paolo, Ferro, Antonella, Tamberi, Stefano, Febbraro, Antonio, Natale, Donato, Maio, Massimo Di, Califano, Daniela, Scognamiglio, Giosuè, Lorusso, Domenica, Canevari, Silvana, Losito, Simona, Gallo, Ciro, Pignata, Sandro
التنسيق: Artigo
اللغة:Inglês
منشور في: Impact Journals LLC 2016
الموضوعات:
Research Paper
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5341934/
https://ncbi.nlm.nih.gov/pubmed/27655643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12056
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة